^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CRL4-CRBN E3 ubiquitin ligase modulator

    Related drugs:
    6d
    Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse (clinicaltrials.gov)
    P2, N=65, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Oct 2027 --> Dec 2028 | Trial primary completion date: Jan 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    golcadomide (CC-99282)
    6d
    Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=720, Not yet recruiting, Dana-Farber Cancer Institute
    New P3 trial
    |
    TP53 (Tumor protein P53)
    |
    clonoSEQ®
    |
    bortezomib • dexamethasone • iberdomide (CC-220) • Lynozyfic (linvoseltamab-gcpt) • Sarclisa subcutaneous (isatuximab subcutaneous) • captisol-enabled melphalan
    8d
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Oct 2026 --> Aug 2028 | Trial primary completion date: Apr 2026 --> Aug 2028
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ®
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    13d
    Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Allison Winter
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • pemetrexed • dexamethasone • golcadomide (CC-99282)
    18d
    Isa Iber VD: A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant (clinicaltrials.gov)
    P1/2, N=88, Not yet recruiting, Dana-Farber Cancer Institute
    New P1/2 trial
    |
    bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • iberdomide (CC-220)
    22d
    Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    iberdomide (CC-220)
    27d
    Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=26, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Tecvayli (teclistamab-cqyv) • iberdomide (CC-220)
    30d
    Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, City of Hope Medical Center
    New P1/2 trial
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    1m
    GEM-IBERDARAX: Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. (clinicaltrials.gov)
    P2, N=140, Active, not recruiting, PETHEMA Foundation | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Darzalex (daratumumab) • dexamethasone • iberdomide (CC-220)
    1m
    Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer. (PubMed, J Proteome Res)
    Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.
    Journal
    |
    IKZF2 (IKAROS family zinc finger 2)
    |
    pomalidomide • iberdomide (CC-220) • mezigdomide (CC-92480)
    2ms
    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Mayo Clinic | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
    2ms
    Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: May 2026 --> Jul 2026
    Trial initiation date
    |
    cyclophosphamide • topotecan • Qarziba (dinutuximab beta) • iberdomide (CC-220) • Unituxin (dinutuximab) • Leukine (sargramostim)